Palisade Bio (NASDAQ:PALI – Get Free Report) and Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.
Risk & Volatility
Palisade Bio has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
Earnings & Valuation
This table compares Palisade Bio and Aquestive Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palisade Bio | $250,000.00 | 770.27 | -$16.78 million | ($0.48) | -2.30 |
| Aquestive Therapeutics | $54.09 million | 8.60 | -$83.78 million | ($0.65) | -5.70 |
Palisade Bio has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Palisade Bio and Aquestive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palisade Bio | N/A | -33.47% | -31.79% |
| Aquestive Therapeutics | -144.63% | N/A | -52.40% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Palisade Bio and Aquestive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palisade Bio | 1 | 0 | 8 | 2 | 3.00 |
| Aquestive Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Palisade Bio currently has a consensus target price of $9.29, suggesting a potential upside of 740.34%. Aquestive Therapeutics has a consensus target price of $8.60, suggesting a potential upside of 132.06%. Given Palisade Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than Aquestive Therapeutics.
Summary
Palisade Bio beats Aquestive Therapeutics on 11 of the 15 factors compared between the two stocks.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
